Nemaura Medical Inc. (NMRD) Research
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles. The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.
Market snapshot
- Symbol
- NMRD
- Price
- $0.00
- Day change
- -50.00%
- Market cap
- $4.0K
- P/E ratio
- -0.00x
- 52-week range
- 0.00001-0.0005
- Sector
- Healthcare
- Industry
- Medical - Devices
- Next earnings
- in 2 months
Peer companies
Recent insider activity
- Ghadar-Ghadr Arash — P-Purchase (100000 shares) on 2024-01-05
- Ghadar-Ghadr Arash — trade (0 shares) on 2022-01-05
- Natha Salim — A-Award (8000 shares) on 2022-01-28
- Moore Thomas Peter — A-Award (8000 shares) on 2022-01-28
- Mclarney Justin James — A-Award (22293 shares) on 2022-01-31
Open Nemaura Medical Inc. (NMRD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.